Health Care Equipment

CHUNLI MEDICAL

Spring International to Hold AGM on May 26 to Consider Repurchasing up to 10% of H Shares

Spring Care Medical reports a 6.27% increase in Q1 net profit, despite a 5.6% drop in revenue, with improved operating cash flow

SpringMed Publishes 2025 Annual Report, Emphasizing Sales Growth and R&D Directions

CHUNLI MEDICAL released FY2026 Q1 earnings on April 29 After-Market (BJT), actual revenue HKD 245.99 M, actual EPS HKD 0.1813

CHUNLI MEDICAL to Release FY2026 Q1 Earnings on April 29 After-Market (BJT)

Spring Medical Announces Revenue and Profit Growth in 2025 and Dividend Plan

CHUNLI MEDICAL to release FY2025 earnings report on March 30, 2026, during market hours (BJT), with forecast revenue of HKD 1.274 B and EPS of HKD 0.8229

Spring Medical 2025 Annual Performance: Significant Growth in Revenue and Net Profit

Spring Medical's net profit increased by 117.72% in 2025

CHUNLI MEDICAL released FY2025 Q4 earnings on February 27 During-Market (BJT), actual revenue HKD 322.12 M, actual EPS HKD 0.2332

CHUNLI MEDICAL released FY2025 earnings on February 27 During-Market (BJT), actual revenue HKD 1.143 B (forecast HKD 1.334 B), actual EPS HKD 0.776 (forecast HKD 0.8229)

Spring Medical Announces Significant Increase in Net Profit for 2025

Spring Medical's shareholder resolutions not approved

Spring Medical uses idle fundraising proceeds to subscribe to Beijing Bank structured deposits

Huansan Securities Releases Report, Giving Spring Medical 'Buy' Rating

Chunli Medical Reports Strong Q3 2025 Profits, Enhanced Earnings Capacity

Spring Medical Obtains New Patent for Implant Prosthesis and Limb Sealing Device

CHUNLI MEDICAL released FY2025 Q3 earnings on October 30 After-Market (BJT), actual revenue HKD 293.51 M, actual EPS HKD 0.2182

CHUNLI MEDICAL released FY2025 9 Months earnings on October 30 After-Market (BJT), actual revenue HKD 821.79 M, actual EPS HKD 0.543

CHUNLI MEDICAL FY2025 Q3 Earnings Release on October 31, 2025, After-Market (BJT)

CH DEMETER FIN

FAMEGLOW

LUEN THAI

NEW GONOW RV

REF HOLDINGS

PARADISE ENT

WEBX HOLDING

HAICHANG HLDG

BEST FOOD HLDG

INTELLIMARK W27

Ordinary dividend (cash)

Ex Date: 2026.05.28, Cash dividend 0.1697 HKD

01858

688236

Beijing Chunlizhengda Medical Instruments Co., Ltd. has proposed a final cash dividend of RMB 1.5 per 10 shares for the financial year ending 31 December 2025, pending shareholder approval on 26 May 2026. The dividend for H shareholders will be paid in Hong Kong dollars, with details on the exchange rate to be announced later. The ex-dividend date is set for 28 May 2026, with a record date of 1 June 2026 and a payment date of 30 June 2026. The company also clarified withholding tax rules for various investor categories.

Tip Ranks

Chunli Medical

Beijing Chunlizhengda Sets Final 2025 Dividend, Clarifies Withholding Tax Rules

02659

02635

00819

02591

06869

02442

02650

01907

00631

BAO PHARMA-B(02659) fell 65.55%, with a trading turnover 785.1 Million HKD, and a year-to-date fell 66.7%. NUOBIKAN(02635) fell 31.2%, with a trading turnover 281.8 Million HKD, and a year-to-date fell 47.2%. TIANNENG POWER(00819) fell 27.25%, with a trading turnover 720.0 Million HKD, and a year-to-date fell 19%.

Top Gainers&Losers

BAO PHARMA-B

NUOBIKAN

TIANNENG POWER

INNOGEN-B

YOFC

EASY SMART GP

ZHIDA TECH

CHINA RISUN GP

SANY INT'L

Top 10 HK Stock Losers (4.30)

Beijing Chunlizhengda Medical Instruments Co., Ltd. (HK:1858) has announced a class meeting for H-shareholders on May 26, 2026, to consider a resolution for a buyback of up to 10% of its H shares. This mandate will empower the board to set terms for the repurchase based on market conditions and regulatory requirements, impacting the company's capital structure and shareholder value. Chunlizhengda specializes in medical devices and is listed in Hong Kong.

T. Rowe Price Intl Equity Research ETF

Chunlizhengda Seeks Mandate for Up to 10% H-Share Buyback

01276

688428

600276

02196

600196

09969

Over half of listed Chinese drugmakers reported increased net profits for 2025, driven by innovative medicines and overseas business. Notable performers include Hengrui Pharmaceuticals, with a 22% profit rise to CNY7.7 billion, and InnoCare Pharma, achieving its first profit of CNY642 million. Fosun Pharmaceutical Group's net profit rose 22% to CNY3.4 billion, while Chunlizhengda Medical Instruments saw a 118% profit surge. The industry is focusing on innovative R&D and adapting to evolving consumer demands, with firms emphasizing integration of online and offline services.

Yicai

HENGRUI PHARMA

InnoCare Pharma

Hengrui Pharma

FOSUN PHARMA

INNOCARE

Over Half of Listed Chinese Drugmakers See 2025 Profit Grow Buoyed by Innovative Medicines, Overseas Business

Chunli Medical announced its full-year results for the year ended December last year, with a revenue of RMB 1.046 billion, an increase of 29.8% year-on-year. The net profit was RMB 273 million, an increase of 118.1% year-on-year; earnings per share were RMB 0.71. It plans to declare a final dividend of RMB 1.5 for every 10 shares, which is RMB 0.15 per share, compared to RMB 0.049 per share in the same period last year

AASTOCKS

"Performance" Chunli Medical's annual net profit is 273 million RMB, an increase of 118%, with earnings per share of 0.15 RMB

CHUNLI MEDICAL announced its performance preliminary report for the year 2025, achieving total operating revenue of 1.044 billion RMB (same below), an increase of 29.5% year-on-year. It recorded a net profit of 272 million RMB, a growth of 117.7%, with earnings per share of 0.71 RMB

"Performance" Chunli Medical's annual net profit is 272 million RMB, an increase of 117.7%

CHUNLI MEDICAL issued a profit warning, expecting a net profit attributable to the owners of the parent company to be between RMB 245 million and RMB 288 million for the fiscal year 2025, representing a growth of 96%-130.4% compared to the previous year. The reason is that the company's various product lines have gradually released growth potential after being included in centralized procurement, while the company steadily advances its international business layout, promoting continuous, stable, and healthy development of operating income both domestically and internationally

"Profit Alert" Chunli Medical forecasts annual net profit to increase by at least 96% to 245 million RMB

Beijing Chunlizhengda Medical Instruments Co., Ltd. (HK:1858) forecasts a significant increase in profitability for 2025, expecting net profit attributable to shareholders to rise by 96% to 130%, reaching RMB244.99 million to RMB287.99 million. The growth is attributed to centralized procurement inclusion, international expansion, and improved operational management. The latest analyst rating for the stock is a Buy, with a price target of HK$18.50. The company specializes in orthopedic medical instruments and is expanding its international presence.

Beijing Chunlizhengda Forecasts Profit to Nearly Double in 2025 on Procurement and Overseas Growth

On January 27th, CHUNLI MEDICAL (1858.HK) experienced a day of low-volume fluctuations and consolidation, with bulls continuously retreating. The stock price repeatedly broke below the key support level of 14.5 yuan, showing extremely weak rebound momentum. The market frequently saw large sell orders, with intraday lows being refreshed continuously, indicating that the main force's willingness to buy is very limited. The medical device sector is generally defensive, with limited recent changes in industry policies, and the actual order volume from last week's new bidding policy did not show significant growth. Leading companies lack performance highlights, and institutions are generally adopting a wait-and-see approach. CHUNLI MEDICAL itself has no major information-driven catalysts, making it difficult to attract incremental capital inflows. 

From a technical perspective, MACD and KDJ are both weakening, forming a typical bearish arrangement. Short-term trading is cooling down, and there is no divergence from the main force. If large buy orders appear against the trend or new medical policy stimuli emerge, it could be seen as a temporary stabilization signal. Otherwise, the market should still be defensive. Overall, CHUNLI MEDICAL is constrained by a weak structure, and if the key support remains unstable, there is a risk of inertia downward. It is recommended that investors maintain flexible positions, pay attention to intraday trading volume and industry news trends, and strictly control risk exposure until clear signals emerge on the right side

Technical Forecast

Morning Trend | CHUNLI MEDICAL Bulls Retreat, Can the Support Boundary Hold?

CHUNLI MEDICAL(01858.HK)